Register for December 1 FDA Workshop on Cardiovascular Toxicities in Immunotherapy Trials

Get Permission

THE U.S. FOOD & DRUG ADMINISTRATION (FDA) and the Oncology Center of Excellence (OCE) will host a complimentary public workshop, Assessment of Cardiovascular Toxicities in Immuno-Oncology Trials, on December 1. ASCO is supporting the workshop with the American College of Cardiology (ACC), the American Heart Association (AHA), and the American Association for Cancer Research (AACR). 

The workshop will focus on identifying best practices to assess cardiovascular and metabolic toxicities in patients receiving cancer immunotherapies. It will also provide a forum for discussion of cardiovascular toxicities in immuno-oncology clinical trials. 

Onsite attendance is limited to the first 110 people who register; however, there will be a webcast available to all who register. More information on the webcast, including the link, will be made available by FDA closer to the workshop date. 

Register at Dec1CardioOnc. ■

© 2017. American Society of Clinical Oncology. All rights reserved.




By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.